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Abstract 
Background: Using the REDS-III recipient and donor databases, we performed a retrospective analysis of 
platelet use in 12 U.S. hospitals that were participants in REDS-III. 
Study Design and Methods: Data were electronically extracted from participating transfusion service 
and blood center computer systems, and from medical records of the 12 REDS-III hospitals. All platelet 
transfusions from 2013-2016 given to patients 18 and older  were included in the analysis. 
Results:  There were 28,843 inpatients and 2,987 outpatients who were transfused with 163,719 
platelet products (103,371 apheresis, 60,348 whole blood derived).  93.5% of platelet products were 
leukocyte reduced and 72.5% were irradiated. 46% were transfused to patients with an ICD 9/10 
diagnosis of leukemia, MDS or lymphoma. The general ward and the ICU were the most common issue 
locations. Only 54% of platelet transfusions were ABO identical; and 60.6% of platelet transfusions given 
to Rh negative patients were Rh positive. The most common pre-transfusion platelet count range for 
inpatients was 20,000-50,000/µL, for outpatients it was 10,000-20,000/µL. Among ICU patients, 35% of 
platelet transfusion episodes had a platelet count of greater than 50,000/µL, this was only 8% for 
general ward and 2% for outpatients. The median post-transfusion increment ranged from 12,000-
20,000/µL for inpatients, and from 17,000-27,000/µL for outpatients.  
Conclusions:  These data from one of the largest reviews of platelet transfusion practice to date provide 
guidance for where to focus future clinical research studies [i.e. platelet use for moderate 
thrombocytopenia (20,000 to 100,000/μL), anticoagulation and platelet use in oncology patients, 
platelet use prior to a procedure] and platelet Blood Management programs. 
Key words: platelet transfusions, transfusion episode, platelet count increment, encounter 
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Introduction 
Platelets are a commonly transfused blood product with recent American Red Cross data 
estimating approximately 7,000 units of platelets being transfused daily in the United States; the 
majority of these are apheresis platelets1-3. Recently, platelet use has plateaued following a number of 
years in which it showed annual increase. This is in sharp contrast to the dramatic decrease in red cell 
transfusions over the past decade.  Indications for platelet use vary and, in an attempt to improve 
clinical practice, several clinical practice guidelines for platelet transfusion have been published 4,5,6. The 
evidence supporting the recommendations in these guidelines is most robust in the 
hematology/oncology and stem cell transplant settings where prophylactic use of platelets at specific 
platelet count thresholds is common. Results are somewhat equivocal concerning the benefit of this 
practice7-10. Furthermore, even with these diagnoses, the evidence for transfusion in specific clinical 
scenarios (e.g. lumbar puncture, invasive procedures, concomitant anti-coagulation therapy, moderate 
thrombocytopenia) is weak or not available. There are even fewer data with regard to the efficacy and 
thresholds for appropriate platelet transfusions in surgical or trauma settings.  
In the 2015 AABB Platelet Transfusion Guidelines, the authors commented that large databases 
could assist with providing background information to inform the design of clinical trials or observational 
studies on platelet transfusion practice. However, analyses of large databases that contain granular 
information on platelet use has been lacking. We are aware of only a few including the Society of 
Thoracic Surgery database on blood use in cardiac surgery that have provided substantial data on 
platelet use11-15. 
Furthermore, a 2012 study from the United Kingdom which compared local practice with 
national standards found differences in practice versus standards. The authors indicated the need for 
reinforcement of guidelines for prophylactic platelet transfusion in hematological disease and for 
screening of platelet use in cardiac surgery16.  Given these limited studies and the potential for 
extending existing Patient Blood Management programs for red cell transfusion into the realm of 
platelet transfusion practice (provided that current usage patterns are well understood), we performed 
a retrospective observational data analysis of platelet use in 12 U.S. hospitals that were participants in 
the Recipient and Donor Epidemiology Study-III (REDS-III).  
 
Methods 
 The infrastructure of the NHLBI Recipient Epidemiology and Donor Evaluation Study III (REDS-III) 
Domestic program has been described previously17. REDS-III is a consortium of hubs, each consisting of a 
blood center and two to four affiliated hospitals, a single central laboratory, and a data coordinating 
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center. Data from 12 US hospitals comprising the REDS-III Recipient Database, which has been 
previously described in detail18, were utilized to study recipient characteristics of platelet transfusions.  
A linked Components database was used to study blood donor and product characteristics. Data studied 
included those extracted electronic data from participating transfusion service/blood center 
(Components) and electronic health records from each participating hospital (Recipient) using a 
conserved specification created by the REDS-III program. All inpatient and outpatient platelet 
transfusions between January 2013 and December 2016 were included in the analysis, excluding 
transfusions among patient less than 18 years of age. 
 Information on component products and manufacturing, including leukoreduction, irradiation, 
and donor blood group and type were extracted from the REDS-III Components database. Linkage of 
blood components to transfusion recipients was performed using an obfuscated blood product donation 
identifier assigned at the domestic hubs. Recipient factors were extracted from the REDS-III Recipient 
Database demographics table. Patient ABO and Rh blood type and pre- and post-transfusion laboratory 
data were collected from the Laboratory table. Patient location within the hospital, medication use, and 
mortality were assessed using the transfers, medication, and encounter tables, respectively. Diagnosis 
codes were extracted from the table of the same name and collated into HCUP categories (e.g. Diseases 
of the Circulatory System). Aggregated data were assessed for normality. Mean and standard deviation 
were used to describe normally distributed data, whereas median and interquartile range (IQR) were 
used to describe the non-normally distributed data. Data manipulation was performed in SAS. 
  
Definitions 
 Patient encounter: A patient encounter was defined as any unique inpatient admission or 
outpatient visit that was documented with a unique start date and time and with a discharge date.  
Many patients had multiple encounters. 
 Transfusion episode: All platelet products issued within an 8 hour interval beginning with 
issuance of the first platelet product for the encounter. 
 Pre-transfusion Platelet Count: the nearest platelet count up to 24 hours prior to the first 
transfusion of the episode for inpatients; and up to 48 hours for outpatients. 
 Post-transfusion Platelet Count: the nearest platelet count up to 24 hours after the last platelet 
transfusion of the episode for inpatients; up to 48 hours for outpatients. Occasionally a post-platelet 
count for one episode is the pre-transfusion platelet count for the next transfusion episode. 
 ABO type specific platelet transfusions: the ABO type of the patient and the platelet product 
were identical (i.e. A to A, O to O). 
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 ABO compatible platelet transfusionsmajor mismatch: the ABO type of the patient and the 
platelet product were not identical and there was no donor plasma antibody incompatibility (i.e. A to O, 
B to O). 
 ABO incompatible platelet transfusionsminor mismatch: the ABO type of the patient and the 
platelet product were not identical and there was donor plasma incompatibility (i.e. O to A, A to B). 
 Platelet product: one apheresis platelet or a pool of whole blood derived platelets (WBD).  
 
Results 
Tables 1 and 2 list patient and product characteristics. 163,719 individual platelet products 
(103,371 apheresis, 60,348 whole blood derived (WBD)) were transfused into 31,821 individual patients 
(60.5% males, 39.5% female). Patients 50-69 years were the most common age group to be transfused 
with platelets. The most common locations for platelet transfusion were the General Ward (52.7%), 
followed by the Intensive Care Unit (28.2%) and the Operating Room (12.6%).  The top three broad 
categories by diagnosis codes (inpatient only) were Hematology/Oncology, Circulatory system, and 
Injury and Poisoning. 93.5% of the platelet products were leukocyte reduced, while 72.4% were 
irradiated. The majority of patients received at least one other type of blood product with red blood 
cells being the most common, followed by plasma and cryoprecipitate.  The mean number (over the 
entire four year study period) of RBC units administered to patients who received at least one platelet 
over the four years of data collection was 6.3 (SD 11.1), for plasma 3.5 (SD 12.8) while 2.6% of patients 
receiving a platelet transfusion also received cryoprecipitate (Data not shown). Of the 31,821 patients 
during the four year study period, 15.8% had expired by the end of the study period. 
 Table 3 lists platelet transfusions by ABO and Rh product and patient type. For ABO only, 54.1% 
of transfusions were ABO-identical ranging from 49.5% for group O to 19.4% for group AB patients. For 
all group O platelets, 29.7% (11,435) were transfused to non-type O patients, while 47.0% (25,689) of all 
group A platelets were given to non-type A patients, with most going to group O patients, a major 
mismatch.  Overall, 16% of platelet transfusions were ABO incompatible minor mismatch in that there 
were ABO antibodies in the donor plasma directed against corresponding antigens on the transfused 
recipient’s red cells. For Rh, 9.8% of all Rh positive platelets were transfused to Rh negative patients. Rh 
negative patients were commonly transfused with Rh positive platelets; 60.6% of their platelet 
transfusions were Rh positive. 
 The mean number of platelet products transfused per episode for inpatients was 1.30 (range 1-
24). 78% of platelet transfusion episodes were comprised of 1 platelet product, 17% two platelet 
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products, 2.5% three platelet products and 1.9% of four or more. There were 77 episodes where 10 or 
more platelet products were transfused.  
Table 4 depicts pre-platelet transfusion count with post-transfusion platelet count increment for 
inpatient and outpatient episodes. Figures 1 and 2 present similar results for the General Ward and ICU.  
The most common pre-transfusion platelet count range for inpatients was 20,000-50,000/µL; for 
outpatients, it was 10,000-20,000/µL. The range of 20,000-50,000/µL was most common for the General 
Ward and ICU, but not for the OR which had a higher pre-transfusion platelet count.  42% of platelet 
transfusion episodes for inpatients had a platelet count of 20,000/µL or less. Among ICU patients 35% of 
platelet transfusion episodes had a pre-transfusion platelet count >50,000 vs. 8% for the general ward 
and only 2% for outpatients. Disregarding inpatients with pre-transfusion platelet count greater than 
100,000/µL, the median post-transfusion increment ranged from 12,000-20,000/µL across patient 
groups with different pre-transfusion platelet levels. For outpatients, the median increment ranged from 
17,000-27,000/µL. For inpatients the median time from time of issue to post-platelet count was 6.9 
hours, and for outpatients, it was 16 hours. Almost half of the outpatient episodes did not have a pre or 
post count that fit the definition for inclusion. 
 There were 5,983 episodes where patients were on anti-platelet medications (aspirin and/or 
Clopidogrel). The median pre-transfusion platelet count for these patients was 83,000/µL (42,000-
180,000/µL, IQR) while for patients not on anti-platelet medication the median pre-transfusion platelet 
count was 19,000/µL (11,000-43,000/µL, IQR). 
 46% of all platelet units were transfused to patients who had a primary or secondary ICD9/10 
diagnosis code of leukemia, myelodysplastic syndrome (MDS) or lymphoma. These patients were 
transfused, on average, more platelets per encounter and per total study period (Table 5). 
 
Discussion 
 The REDS-III Recipient and Component databases represent one of the largest data sets 
available addressing both component and patient clinical characteristics, and we estimate it represents 
roughly 3-5% of all platelets transfused annually in the United States2,3. Other large international 
databases are available that have been used to address a number of donor and patient transfusion 
issues, but may lack the granularity and depth of the REDS-III database11-15,19. Our data confirm that 
apheresis platelets are the most common platelet transfusion product, though our data shows less 
apheresis use than national surveys due to one of the four HUBS manufacturing large numbers of WBD 
platelets.  Not surprisingly, nearly all platelet products were leukocyte reduced since all apheresis 
platelet products are automatically leukocyte reduced by apheresis technology. Irradiation of platelet 
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products is common, partly reflecting high platelet use in the oncologic/stem cell transplant setting. The 
General Ward (mainly representing oncology and stem cell transplant patients) and ICU dominated as 
the locations for platelet transfusions and have similar transfusion practices. Any Patient Blood 
Management program addressing platelet transfusion practice will need to primarily focus on these two 
locations. 
 Post-transfusion platelet count increments were under 20,000/µL for the majority of inpatient 
transfusion regardless of location. Data from the recent PLADO trial showed a similar but slightly higher 
4 hour platelet increment for their median and high dose arms20. The differences may reflect a lesser 
acuity of illness in their patients compared to our study or the shorter interval for post-transfusion 
platelet counts vs. 6.9 hours in this study. Outpatient transfusions led to a higher median post-
transfusion platelet count increment, most likely reflecting a lower severity of illness than in the 
inpatient setting. We selected post platelet transfusion platelet count increments as the measure of 
platelet count rise rather than corrected count increments (CCI) because they reflect the “real life 
values” upon which physicians make decisions. CCI are most useful in determining platelet 
refractoriness, a condition not studied in this project. 
 Surprisingly, a pre-transfusion platelet count of 20,000-50,000 was the most common platelet 
count prior to transfusion. This was true for both General Ward and ICU. Current recommendations for 
prophylactic platelet transfusion for oncology and bone marrow transplant are 10,000/μL and for minor 
bleeding, 20,000/μL4,5. Transfusions in the 20,000/μL to 100,000/μL range is an area that requires 
further study in that evidence based data is limited and weak. There are virtually no good evidence 
based data that address platelet transfusion practice for these patients. In the ICU setting there are a 
large number of platelet transfusion episodes for pre-transfusion platelet counts of 50,000-100,000/µL 
or greater than 100,000/µL. Again the evidence based data for this practice is weak. A recent United 
Kingdom observational study of thrombocytopenia and platelet transfusion in the ICU reported that 
greater than 40% of platelet transfusions were given with a patient platelet count >50,000/µL similar to 
the 35% we observed. Many platelet transfusions were given to non-bleeding patients, and platelet 
count increments were similar to our data for ICU patients. They concluded the importance of the need 
for improved evidence for platelet use in this population of patients21. A more recent retrospective, 
three academic center study of patients transfused with platelets in the ICU demonstrated that platelet 
transfusions were not associated with increased risk of death in critically ill patients. They found that 
median pre-transfusion platelet count was 55,000/µL for medical ICU patients and 95,000/µL for general 
surgery patients. They emphasized the need for further prospective studies to address the benefits and 
harms of platelet transfusions in critically ill patients11. 
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 Our data demonstrate that only 54.1% of platelet transfusions were ABO type specific. 29.7% of 
type O platelets were transfused to non-type O patients. These practices illustrate the difficulty that 
collection centers have in maintaining an adequate platelet inventory that would allow for more type-
specific transfusion. Though the risk of a severe or even life-threatening hemolytic transfusion reaction 
is very low, it is clear that with 1 in 10 platelet transfusions being an O platelet to a non-O patient and 
16% overall ABO antibody incompatibilityminor mismatch, our data indicates exposure to this risk is 
occurring on a daily basis.  There are also reports of adverse outcomes when patients receive non-ABO 
type specific blood productplatelets, including decreases in platelet increment, increased 
alloimmunization, and increase in febrile reactions22,23. Pai et al recently reported the transfusion of ABO 
non-identical blood is associated with worsened mortality outcomes in group A patients. The 
mechanism was not clear, though it was thought unlikely to be due to donor plasma  
productscomponents, this explanation could not be ruled out24. Our data show that use of non-type 
specific platelet transfusions is common, supporting the need for further studies to clarify the risk for 
adverse events. Our data are similar to a recent BEST Collaborative international survey which 
demonstrated wide variability in practices associated with the transfusion of ABO incompatible 
mismatched platelets19. Though we did not analyze the impact of major mismatched platelets on 
platelet increment, Triulzi et. al. analyzed this as part of the Platelet Dose Study (PLADO). They 
demonstrated that there was a small (approximately 25%) but statistically significant decrease in 
corrected count increment for major mismatched platelets. However, they importantly demonstrated 
that there was no impact on the risk of bleeding when compared to ABO identical platelets25. In our 
study, 60.6% of all transfusions given to Rh negative patients were Rh positive thereby posing the risk of 
anti-D alloimmunization. A review of this topic in the 2017 ASCO guidelines for platelet transfusion in 
cancer patients states that whereas older literature indicated a rate of anti-D alloimmunization of 
greater than 7%, current studies suggest a much lower alloimmunization rate of about 1%4. 
 The number of patients on anti-platelet therapy continues to rise. Our data demonstrate that 
patients on aspirin and/or Clopidogrel had pre-transfusion platelet counts significantly higher than for 
patients not on these medications. The higher pre-transfusion platelet count for ICU and surgery 
patients may be partly reflected by use of these drugs for patients undergoing cardiac surgery. Although 
the impact of these drugs on platelet function is well-understood, the efficacy of platelet transfusion to 
prevent or treat bleeding is poorly understood, and is in definite need of further clinical evaluation as 
suggested in a recent review of this clinical issue256. 
 Our study has a number of limitations. Although the number of platelet transfusions evaluated 
is extremely large, it represents only 12 hospitals in the U.S. and is weighted towards academic medical 
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centers. Though the study was epidemiological in nature, the lack of data on the efficacy to prevent or 
treat bleeding is evident. Because of inability to match component product and recipient ABO and Rh 
type for all products, the number of platelet transfusions for evaluation by ABO and Rh type was 
reduced. Diagnosis and procedure codes were not the emphasis of this paper so data are limited to 
general diagnostic codes. Platelet transfusions on the General Ward were assumed to represent mainly 
Hematology/Oncology and stem cell transplant patients, though we have no direct proof that is so. 
Platelet transfusions in pediatric patients were not part of this study, so no comment can be made as to 
platelet transfusion practice in pediatric patients. 
 In summary, our data represent one of the largest studies of platelet transfusion practice to 
date. Despite some weaknesses, this database has a wealth of information concerning platelet 
transfusion practices in the inpatient and outpatient setting, using data from both community hospitals 
and academic institutions. This study has emphasized areas of platelet transfusion practice that are 
poorly defined. It will lead to the creation of new clinical research questions as well as to help direct 
platelet Patient Blood Management Program efforts. Opportunities for further research include platelet 
use for moderate thrombocytopenia (platelet counts between 20,000 and 100,000/μL), anticoagulation 
and platelet use in oncology patients, platelet use prior to a procedure, and the role of platelet 
transfusions for patients on anti-platelet medications. Finally, these data highlight “real world” versus 
controlled trial studies and provide epidemiologic and laboratory data to support new initiatives to 
improve platelet transfusion practice. 
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Table 1. Characteristics (by number and %) of patients with an encounter that  
 included a platelet transfusion 
Number of Patient-Total 31,821 
Inpatients 28,843 (91%) 
Outpatients   2,978 (9%) 
Male (%) 19,264 (60.5%) 
Female (%) 12,554 (39.5%) 
Age (Years)   18-29   1,475 (4.6%) 
                       30-49   4,425 (13.9%) 
                       50-69 15,265 (48.1%) 
                       70 & >  10,656 (33.4%) 
Race (%)        White 23,876 (75%) 
                       Black   3,177 (9.9%) 
                       Asian       843 (2.6%) 
                       Other  3,925 (12.3%) 
Alive at last encounter 26,803 (84.2%) 
Dead at last encounter*   5,018 (15.8%) 
*Hospital mortality at any time during the four year study interval 
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Table 2. Platelet products issued, location issued and broad ICD 9/10 Diagnosis Codes  
Platelet Products (Units)-Total 163,719 
Apheresis 103,371 (63%) 
Whole Blood Derived  60,348 (37%) 
Leukocyte Reduced         93.5% 
Irradiated               72.5% 
Outpatient   25,582 (16%) 
Inpatient 138,137 (84%) 
    General ward   72,787 (52.7%) 
    ICU   38,944 (28.2%) 
    OR   17,370 (12.6%) 
    Emergency Department     4,504 (3.3%) 
    Other procedure suite         291 (0.2%) 
    Other      4,241 (3.0%) 
ICD 9/10 Diagnosis Code: Inpatient (%) 
 
    Disease of the Circulatory System           23.2% 
    Neoplasms           18.6% 
    Diseases of blood & blood forming organs            5.6%     
    Injury & Poisoning          16.2%  
    Disease of Digestive System             9% 
ICD 9/10 Diagnosis Code: Outpatient (%)   
    Neoplasms & Diseases of blood & blood   
    forming organs 
          83% 
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Table 3. Platelet transfusions by ABO and Rh product type 
Platelet Product ABO Type 
Patient ABO A B AB O Total 
% ABO 
Identical 
A 28,927 3,546 2,444 7,518 42,435 68.1 
B 3,969 6,598 1,276 2,944 14,787 44.7 
AB 3,227 665 1,173 973 6,038 19.4 
O 18,493 6,593 2,377 27,001 54,464 49.5 
Total 54,616 17,402 7,270 38,436 117,724 54.1 
Platelet Product Rh Type 
Patient Rh Rh Positive Rh Negative Total % Rh “Identical” 
Rh Positive 69,663 6,216 75,879 91.8 
Rh Negative 7,548 4,912 12,460 39.4 
Total 77,211 11, 128 88,339 84.4 
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Table 4. Pre-platelet transfusion count (range and median count within that range) 
 with post-transfusion increment by episode 
 
Pre-Tx Plt Ct per ul 
(Median) 
Total 
Episodes 
% of 
Total 
Median Post-
Tx Plt Ct 
Increment 
per ul* 
Inpatient 
Transfusions 
No results 9,689 9% 
 
≤10,000 
(8,000) 
21,367 20% 12,000 
>10,000-20,000 
(15,000) 
23,390 22% 13,000 
>20,000-50,000 
(36,000) 
30,046 28% 17,000 
>50,000-100,000 
(68,000) 
11,223 11% 20,000 
>100,000 
(187,000) 
10,204 10% -6,000 
Outpatient 
Transfusions 
No results 11,038 47% 
 
≤10,000 
(7,000) 
4,128 17% 27,000 
>10,000-20,000 
(15,000) 
5,906 25% 24,000 
>20,000-50,000 
(29,000) 
2,300 10% 20,000 
>50,000-100,000 
(61,000) 
222 1% 17,000 
>100,000 
(189,000) 
136 1% -7,500 
*Median time from time of issue to post-platelet count: 6.9 hours (inpatients) 
                                                                                                        1.6 hours (outpatients) 
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Table 5. Platelet use in patients with ICD 9/10 diagnosis of Leukemia, MDS and Lymphoma 
Table 5a. Platelet use in patients with ICD9/10 diagnosis of leukemia/MDS 
Mean platelet products transfused during an encounter 
Any primary or secondary 
diagnosis of leukemia/MDS 
# of encounters 
Mean 
productlatelets 
transfused 
Std. Dev 
NO 36,060 2.6 5.0 
YES 22,742 2.8 5.8 
Mean platelet products transfused to each subject 
NO 27,188 3.4 7.87 
YES 4,386 14.7 19.41 
Table 5b. Platelet use in patients with ICD 9/10 diagnosis of lymphoma 
Mean platelet products transfused during an encounter 
Any primary or secondary 
diagnosis of lymphoma 
# of encounters 
Mean 
productlatelets 
transfused 
Std. Dev 
NO 57,774 2.6 5.37 
YES 4,028 2.8 5.65 
Mean platelet products transfused to each subject 
NO 30,084 4.9 11.2 
YES 1,490 7.6 13.3 
1) 64,400 platelet products transfused with diagnosis of leukemia/MDS 
2) 11,286 platelet products transfused with diagnosis of lymphoma 
3) 46.2% of all platelet products were transfused with diagnosis of leukemia, MDS and lymphoma 
combined 
4) There were 247 patients who had a primary or secondary diagnosis of both leukemia/MDS and 
lymphoma, and were not included in Table 5 data 
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Figure 1. 
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Figure 2. 
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Figure Descriptions 
Fig. 1 The pre-platelet, post-platelet count and platelet increment (all median counts) are presented by 
different pre-transfusion platelet counts. The number of episodes (and % episodes) is also presented. 
The data are for patients who received a transfusion while an inpatient on the hospital general ward. 
 
Fig. 2 The pre-platelet, post-platelet count and platelet increment (all median counts) are presented by 
different pre-transfusion platelet counts. The number of episodes (and % episodes) is also presented. 
The data are for patients who received a transfusion while an inpatient in the hospital ICU. 
 
